This topic contains a solution. Click here to go to the answer

Author Question: A patient taking montelukast (Singulair) for the last 2 months has the following blood laboratory ... (Read 111 times)

Beheh

  • Hero Member
  • *****
  • Posts: 520
A patient taking montelukast (Singulair) for
 
  the last 2 months has the following blood laboratory test values. Which value do you report to the prescriber immediately?
  a. White blood cell count of 10,500 cells/mm3
  b. Lactate dehydrogenase 950 IU/L
  c. Potassium 3.6 mEq/L
  d. Hematocrit 32

Question 2

What condition is a major cause of long-term high blood pressure?
 
  a. Atherosclerosis
  b. Bleeding disorders
  c. Chronic liver disease
  d. Diabetes insipidus



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

juliaf

  • Sr. Member
  • ****
  • Posts: 344
Answer to Question 1

ANS: B

Answer to Question 2

ANS: A




juliaf

  • Sr. Member
  • ****
  • Posts: 344

 

Did you know?

Thyroid conditions may make getting pregnant impossible.

Did you know?

It is important to read food labels and choose foods with low cholesterol and saturated trans fat. You should limit saturated fat to no higher than 6% of daily calories.

Did you know?

Methicillin-resistant Staphylococcus aureus or MRSA was discovered in 1961 in the United Kingdom. It if often referred to as a superbug. MRSA infections cause more deaths in the United States every year than AIDS.

Methicilli ...
Did you know?

Over time, chronic hepatitis B virus and hepatitis C virus infections can progress to advanced liver disease, liver failure, and hepatocellular carcinoma. Unlike other forms, more than 80% of hepatitis C infections become chronic and lead to liver disease. When combined with hepatitis B, hepatitis C now accounts for 75% percent of all cases of liver disease around the world. Liver failure caused by hepatitis C is now leading cause of liver transplants in the United States.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library